84 results on '"Roche, Nicolas"'
Search Results
2. Late Breaking Abstract - Baseline characteristics impact on asthma exacerbation risk: individual patient trial data analysis
3. Blood inflammatory phenotypes and clinical characteristics as determinants of persistent asthma in the Constances cohort
4. Blood basophils, nocturnal cough and asthma in the Constances cohort
5. CAT versus mMRC to allocate COPD patients to clinically relevant phenotypes identified using Classification and Regression Trees
6. Late Breaking Abstract - Consensus quality standard for implementing inhaler regimen switch in patients with respiratory disease
7. The challenges of Process Engineering for the reuse of treated wastewater within INRAE's REUSE network - the need for a multidisciplinary and multi-scale approach.
8. Fate and treatment of pharmaceutical emerging pollutants in the context of wastewater reuse for agricultural irrigation.
9. Late Breaking Abstract - Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)
10. Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
11. Impact of COVID-19 on treatments’ dispensations for chronic airways diseases in France
12. Dyspnea-induced Limitation (DYSLIM), a self-administered questionnaire to evaluate dyspnea-related activity limitation in respiratory disease>
13. Burden of asthma by treatment step in the French CONSTANCES general population cohort
14. Blood inflammatory phenotypes of asthma in the Constances cohort
15. Influenza and pneumococcal vaccination in patients with COPD
16. Sex differences in COPD outcome in 5,355 women with COPD: A new analysis of the 3CIA study
17. Risk charts of five-year mortality in COPD patients
18. Association between occupational exposures to solvents and airway obstruction in the CONSTANCES cohort
19. Occupational exposures to solvents and asthma in the Constances cohort
20. Differentiating asthma from chronic obstructive pulmonary disease (COPD) in medico-economic databases: myth or reality?
21. Burden and drivers of severe hypoxemia in real life patients with stable COPD
22. Ergotact
23. Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT
24. Osteoporosis onset in patients prescribed ICS for COPD: matched cohort study
25. Association between ICS therapy for COPD and diabetes onset and progression
26. Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
27. Comparison of dual vs triple therapies in patients hospitalized for COPD in France: a claims data study
28. Relation between gender and survival among real-life COPD patients
29. Observational study of adherence to indacaterol/glycopyrronium 110/50µg o.d. (IND/GLY) in COPD
30. Asthma control and COPD symptom burden: results from a multi-country observational study (SPRINT) in patients using fixed dose combination (FDC) inhalers
31. DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT)
32. Using Two-Photon Absorption Pulsed-Laser Excitation to Simulate Radiation Effects in Microelectronics
33. Determinants of the 6 minute walking distance and exercise desaturations in COPD: relationships with comorbidities
34. Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients
35. Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study
36. Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK
37. COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study
38. Applicability of randomized controlled trials (RCTs) results to real-life patients in COPD
39. Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study
40. Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
41. Two-photon absorption pulsed-laser single-event effect technique for GaN materials and the impact of deep level traps on the carrier generation process
42. Modeling future COPD epidemiology
43. Automated video analysis of movements in learning the inhaled administration of drugs by patients: A validation study
44. LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice
45. Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
46. Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study
47. Asthma-COPD overlap syndrome (ACOS) versus "pure" COPD: A distinct phenotype?
48. Current burden of uncontrolled asthma in the general population: The OPCRD asthma state of the union study
49. Relationship between blood eosinophil count (Eos), clinical characteristics and mortality of patients with COPD
50. The effects of total ionizing dose on the transient response of SiGe BiCMOS technologies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.